Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 764

2.
4.

Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis.

Iwamoto J, Takeda T, Sato Y, Uzawa M.

Clin Rheumatol. 2007 Feb;26(2):161-7. Epub 2006 Mar 25.

PMID:
16565894
5.

Effects of vibration therapy on bone mineral density in postmenopausal women with osteoporosis.

Ruan XY, Jin FY, Liu YL, Peng ZL, Sun YG.

Chin Med J (Engl). 2008 Jul 5;121(13):1155-8.

PMID:
18710630
6.

Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.

Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.

Menopause. 2013 Jan;20(1):72-8. doi: 10.1097/gme.0b013e31825fe2e8.

PMID:
22968256
7.

Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis.

Iwamoto J, Makita K, Sato Y, Takeda T, Matsumoto H.

Osteoporos Int. 2011 Oct;22(10):2735-42. doi: 10.1007/s00198-010-1495-8. Epub 2010 Nov 23.

PMID:
21104227
8.

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.

McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.

Bone. 2007 Jul;41(1):122-8. Epub 2007 Mar 24.

PMID:
17468062
9.

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.

Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN, Geusens P, Hosking D, Jaeger P, Kaufman JM, Leite M, Leon J, Liberman U, Menkes CJ, Meunier PJ, Reid I, Rodriguez J, Romanowicz A, Seeman E, Vermeulen A, Hirsch LJ, Lombardi A, Plezia K, Santora AC, Yates AJ, Yuan W.

Bone. 1996 Feb;18(2):141-50. Erratum in: Bone 1996 Jul;19(1):78.

PMID:
8833208
10.

Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.

Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G.

Nephrol Dial Transplant. 2009 May;24(5):1472-7. doi: 10.1093/ndt/gfn690. Epub 2008 Dec 15.

PMID:
19075192
11.

Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine.

Guo CY, Weetman AP, Eastell R.

Clin Endocrinol (Oxf). 1997 Mar;46(3):301-7.

PMID:
9156039
12.

Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis.

Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H.

Yonsei Med J. 2008 Feb 29;49(1):119-28. doi: 10.3349/ymj.2008.49.1.119.

13.

Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.

Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.

J Am Geriatr Soc. 2007 May;55(5):752-7.

PMID:
17493196
14.
15.

Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.

Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Weryha G, Marques-Neto JF, Gaines KA, Verbruggen N, Melton ME.

Clin Drug Investig. 2006;26(2):63-74.

PMID:
17163237
16.

Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women.

Stock JL, Bell NH, Chesnut CH 3rd, Ensrud KE, Genant HK, Harris ST, McClung MR, Singer FR, Yood RA, Pryor-Tillotson S, Wei L, Santora AC 2nd.

Am J Med. 1997 Oct;103(4):291-7.

PMID:
9382121
17.

The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis.

Yan Y, Wang W, Zhu H, Li M, Liu J, Luo B, Xie H, Zhang G, Li F.

J Bone Miner Metab. 2009;27(4):471-8. doi: 10.1007/s00774-009-0057-7. Epub 2009 Apr 3.

PMID:
19343272
18.
19.

Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis.

Gonnelli S, Cepollaro C, Pondrelli C, Martini S, Montagnani A, Monaco R, Gennari C.

Calcif Tissue Int. 1999 Nov;65(5):359-64.

PMID:
10541760
20.

Supplemental Content

Support Center